Pharmacological treatment of Parkinson’s disease: life beyond dopamine D2/D3 receptors?
First Online: 04 February 2008 Received: 31 August 2007 Accepted: 30 October 2007 DOI:
10.1007/s00702-007-0852-z Cite this article as: Linazasoro, G., Van Blercom, N., Ugedo, L. et al. J Neural Transm (2008) 115: 431. doi:10.1007/s00702-007-0852-z Summary.
Parkinson’s disease (PD) is a multisystemic disorder in which several neurotransmitters other than dopamine are affected. Drugs acting on non-dopaminergic systems are envisaged as promising agents to treat PD and levodopa-induced dyskinesias (LID). However, compounds targeting glutamate, adenosine, noradrenaline, 5-hydroxytryptamine, cannabinoid, and opioid transmitter systems have been assessed in human studies showing negative, inconsistent or unsatisfactory results. Most of these drugs had been tested previously in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned monkeys, as well as in the classic 6-hydroxydopamine-lesioned rat model. These failures raise several questions and concerns about the true reliability of animal studies, the adequacy of the working hypotheses and design of clinical trials, the validity of tools in current use to evaluate a particular effect, and the selectivity of the drugs used. More importantly, observed discrepancies between the results in models and patients, could challenge the validity of current ideas about the pathophysiology of parkinsonism and LID.
Keywords: Parkinson’s disease; levodopa-induced dyskinesias; non-dopaminergic drugs; animal models
Correspondence: Gurutz Linazasoro, Centro Investigación Parkinson, Policlínica Gipuzkoa, Parque Tecnológico Miramón, 20009 San Sebastián (Gipuzkoa), Spain
References Agid, Y, Graybiel, AM, Ruberg, M, Hirsch, E, Blin, J, Dubois, B, Javoy-Agid, F 1990 The efficacy of levodopa treatment declines in the course of Parkinson’s disease: do nondopaminergic lesions play a role? Adv Neurol 53 83 100 PubMed Bara-Jimenez, W, Dimitrova, T, Sherzai, A, Favit, A, Mouradian, MM, Chase, TN 2004 Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson’s disease Mov Disord 19 1183 1186 PubMed CrossRef Bara-Jimenez, W, Bibbiani, F, Morris, MJ, et al. 2005 Effects of serotonin 5HT 1A agonist in advanced Parkinson’s disease Mov Disord 20 932 936 PubMed CrossRef Baronti, F, Mouradian, MM, Conant, KE, et al. 1992 Partial dopamine agonist therapy of levodopa-induced dyskinesias Neurology 42 1241 1243 PubMed Bartoszyk, GD, van Amsterdam, C, Greiner, HE, Rautenberg, W, Russ, H, Seyfried, CA 2004 Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. Neurochemical profile J Neural Transm 111 113 126 PubMed CrossRef Beal, MF 2001 Experimental models of Parkinson’s disease Nat Rev Neurosci 2 325 332 PubMed CrossRef Bennett, JP, Jr, Landow, ER, Dietrich, S, Schuh, LA 1994 Suppression of dyskinesias in advanced Parkinson’s disease: moderate daily clozapine doses provide long-term dyskinesia reduction Mov Disord 9 409 414 PubMed CrossRef Bezard, E, Ferry, S, Mach, U, et al. 2003 Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function Nat Med 9 762 777 PubMed CrossRef Bibbiani, F, Oh, JD, Chase, TN 2001 Serotonin 5HT1A agonist improves motor complications in rodent and primate parkinsonian models Neurology 57 1829 1834 PubMed Bonifati, V, Fabrizio, E, Cipriani, R, Vanacore, N, Meco, G 1994 Buspirone in levodopa-induced dyskinesias Clin Neuropharmacol 17 73 82 PubMed CrossRef Bracco, F Battaglia, A Chouza, C PKDS009 Study Group 2004 The long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: final results of a 5-year, double-blind, levodopa-controlled study CNS Drugs 18 733 746 PubMed CrossRef Braz, CA, Borges, V, Ferraz, HB 2004 Effect of riluzole on dyskinesia and duration of the on state in Parkinson’s disease patients: a double-blind, placebo-controlled pilot study Clin Neuropharmacol 27 25 29 PubMed CrossRef Brotchie, JM 2003 CB1 cannabinoid receptor signalling in Parkinson’s disease Curr Opin Pharmacol 3 54 61 PubMed CrossRef Calon, F, Rajput, AH, Hornykiewicz, O, Bedard, PJ, Di Paolo, T 2003 Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson’s disease Neurobiol Dis 14 404 416 PubMed CrossRef Carroll, CB, Bain, PG, Teare, L, et al. 2004 Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study Neurology 63 1245 1250 PubMed Cenci, MA, Whishaw, IQ, Schallert, T 2002 Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci 3 574 579 PubMed CrossRef Chaná, P, de Marinis, A, Barrientos, N 1997 Gabapentin and motor fluctuations in Parkinson’s disease Mov Disord 12 608 PubMed CrossRef Chase, TN, Oh, JD 2000 Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications Ann Neurol 47 S122 S130 PubMed Chung, KA, Carlson, NE, Nutt, JG 2005 Short-term paroxetine treatment does not alter the motor response to levodopa in PD Neurology 64 1797 1798 PubMed CrossRef Collins, MO, Husi, H, Yu, L, et al. 2006 Molecular characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome J Neurochem 97 16 23 PubMed CrossRef Doder, M, Rabiner, EA, Turjanski, N, Lees, Aj, Brooks, DJ 2003 Tremor in Parkinson’s disease and serotoninergic dysfunction: an (11)C-WAY 100635 PET study Neurology 60 601 605 PubMed Durif, F, Vidailhet, M, Bonnet, AM, et al. 1995 Levodopa-induced dyskinesias are improved by fluoxetine Neurology 45 1855 1858 PubMed Durif, F, Debilly, B, Galitzky, M, et al. 2004 Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study Neurology 62 381 388 PubMed Fernandez, HH 2006 Istradefylline for the treatment of motor response complications on levodopa in PD: results of the KW-6002-US-018 study focusing on functional and notor improvement Mov Disord 21 S642 Fox, SH, Henry, B, Hill, MP, et al. 2001 Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha-2 adrenoceptor antagonist idazoxan Mov Disord 16 642 650 PubMed CrossRef Fox, SH, Lang, AE, Brotchie, JM 2006 Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase Iia clinical studies: keys to success and roads to failure Mov Disord 21 1578 1594 PubMed CrossRef Frackiewicz, EJ, Jhee, SS, Shiovitz, TM, et al. 2002 Brasofensine treatment for Parkinson’s disease in combination with levodopa/carbidopa Ann Pharmacother 36 225 230 PubMed CrossRef Goetz, CG, Damier, P, Hicking, C, Laska, E, Müller, T, Olanow, CW, Rascol, O, Russ, H 2007 Sarizotan as a treatment for dyskinesias in Parkinson’s disease: a double-blind placebo-controlled trial Mov Disord 22 179 186 PubMed CrossRef Gomez-Mancilla, B, Bedard, PJ 1993 Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys Clin Neuropharmacol 16 418 427 PubMed Guttman, M 2006 Efficacy of istradefylline in Parkinson’s disease patients treated with levodopa with motor response complications: primary efficacy results of the KW-6002-US-018 study Mov Disord 21 S585 Hauser, RA 2006 Efficacy of istradefylline in levodopa-treated Parkinson’s disease patients with motor response complications: secondary efficacy results of the KW-6002-US-013 study Mov Disord 21 S510 Hauser, R Hubble, JP Truong, DD the Istradefylline US-001 Study Group 2003 Randomized trial of the Adenosine A2A receptor antagonist istradefylline in advanced PD Neurology 61 297 303 PubMed Henry, B, Fox, SH, Peggs, D, et al. 1999 The alpha 2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of levodopa in the MPTP-lesioned primate model of Parkinson’s disease Mov Disord 14 744 753 PubMed CrossRef Henry, B, Fox, SH, Crossman, AR, Brotchie, JM 2001 Mu- and delta-Opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease Exp Neurol 171 139 146 PubMed CrossRef Hughes, NR, McKnight, AT, Woodruff, GN, et al. 1998 Kappa-opioid receptor agonists increase locomotor activity in the monoamine depleted rat model of parkinsonism Mov Disord 13 228 233 PubMed CrossRef Imbert, C, Bezard, E, Guitraud, S, Boraud, T, Gross, CE 2000 Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the macaque monkey J Neurosci Meth 96 71 76 CrossRef Jenner, P 2003 The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson’s disease Parkinsonism Relat D 9 131 137 CrossRef Johnston, TH, Brotchie, JM 2006 Drugs in development for Parkinson’s disease Curr Opin Invest Drugs 7 25 32 Kanda, T, Jackson, MJ, Smith, LA, et al. 1998 Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys Ann Neurol 43 507 513 PubMed CrossRef Katzenschlager, R, Manson, AJ, Evans, A, Watt, H, Lees, AJ 2004 Low dose quetiapine for drug induced dyskinesias in Parkinson’s disease: a double blind cross over study J Neurol Neurosurg Psychiatry 75 295 297 PubMed Klintenberg, R, Svenningsson, P, Gunne, L, Andren, PE 2002 Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism J Neural Transm 109 1295 1307 PubMed CrossRef Klockgether, T, Turski, L 1993 Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia Ann Neurol 34 585 593 PubMed CrossRef Lees, AJ, Shaw, KM, Stern, G 1978 Baclofen in Parkinson’s disease J Neurol Neurosurg Psychiatry 41 707 708 PubMed Linazasoro, G 2004 Recent failures of new potential symptomatic treatments for Parkinson’s disease: causes and solutions Mov Disord 19 743 754 PubMed CrossRef Lozano, AM, Carella, F 2002 Physiologic studies in the human brain in movement disorders Parkinsonism Relat Disord 8 455 458 PubMed CrossRef Lyons, KE, Pahwa, R 2006 Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia Clin Neuropharmacol 29 148 153 PubMed CrossRef Mailman, R, Huang, X, Nichols, DE 2001 Parkinson’s disease and D1 dopamine receptors Curr Opin Invest Drugs 2 1582 1591 Manson, AJ, Iakovidou, E, Lees, AJ 2000 Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson’s disease Mov Disord 15 336 337 PubMed CrossRef Manson, AJ, Katzenschlager, R, Hobart, J, et al. 2001 High dose naltrexone for dyskinesias induced by levodopa J Neurol Neurosurg Psychiatry 70 554 556 PubMed CrossRef Mercuri, NB, Bernardi, G 2005 The ‘magic’ of l-dopa: why is it the gold standard Parkinson’s disease therapy? Trends Pharmacol Sci 26 341 344 PubMed CrossRef Merello, M, Nouzeilles, MI, Cammarota, A, Leiguarda, R 1999 Effect of memantine (NMDA antagonist) on Parkinson’s disease: a double-blind crossover randomized study Clin Neuropharmacol 22 273 276 PubMed Merims, D, Ziv, I, Djaldetti, R, et al. 1999 Riluzole for levodopa-induced dyskinesias in advanced Parkinson’s disease Lancet 353 1764 1765 PubMed CrossRef Mesnage, V, Houeto, JL, Bonnet, AM, et al. 2004 Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson’s disease Clin Neuropharmacol 27 108 110 PubMed CrossRef Murata, M, Horiuchi, E, Kanazawa, I 2001 Zonisamide has beneficial effects on Parkinson’s disease patients Neurosci Res 41 397 399 PubMed CrossRef Murata, M Hasegawa, K Kanazawa, I The Japan Zonisamide on PD Study Group 2007 Zonisamide improves motor function in Parkinson’s disease. A randomized, double-blind study Neurology 68 45 50 PubMed CrossRef Nichols, NF, Cimini, MG, Haas, JV, et al. 2002 PNU-96391A (OSU6162) antagonizes the development of behavioural sensitization induced by dopamine agonists in a rat model for Parkinson’s disease Neuropharmacology 43 817 824 PubMed CrossRef Olanow, CW, Damier, P, Goetz, CG, et al. 2004 Multicenter, open-label, trial of sarizotan in Parkinson’s disease patients with levodopa-induced dyskinesias (the SPLENDID study) Clin Neuropharmacol 27 58 62 PubMed CrossRef Olson, WL, Gruenthal, M, Mueller, ME, Olson, WH 1997 Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial Am J Med 102 60 66 PubMed CrossRef Parkinson Study Group 2000 Pramipexole vs levodopa as initial therapy for Parkinson’s disease: a randomized controlled trial JAMA 284 1931 1938 CrossRef Parkinson Study Group 2001 A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease Neurology 56 455 462 Pourcher, E 2006 Safety and tolerability of istradefylline in Parkinson’s disease with motor response complications: results of the KW-6002-US-018 study Mov Disord 21 S508 Qiu, J 2007 Debates on translational research: a balancing act Lancet Neurol 6 208 209 PubMed CrossRef Rascol, O, Fabre, N, Blin, O, et al. 1994 Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson’s disease Mov Disord 9 437 440 PubMed CrossRef Rascol, O, Blin, O, Thalamas, C, et al. 1999 ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson’s disease Ann Neurol 45 736 741 PubMed CrossRef Rascol, O, Brooks, DJ, Korczyn, AD, De Deyn, PP, Clarke, CE, Lang, AE 2000 A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa N Eng J Med 342 1484 1491 CrossRef Rascol, O, Arnulf, I, Peyro-Saint, PH, et al. 2001a Idazoxan, an α-2 antagonist, and L-dopa-induced dyskinesias in patients with Parkinson’s disease Mov Disord 16 708 713 CrossRef Rascol, O, Nutt, J, Blin, O, et al. 2001b Induction by D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson’s disease Arch Neurol 58 249 254 CrossRef Rascol, O, Lees, AJ, Poewe, W, Stalin, L 2006 NS2330, a dopamine reuptake inhibitor, in levodopa-treated patients with Parkinson’s disease and motor fluctuations: the Phase II ADVANS study Mov Disord 21 S515 Richard, IH, Maughn, A, Kurlan, R 1999 Do serotonin reuptake inhibitor antidepressants worsen Parkinson’s disease? A retrospective case series Mov Disord 14 155 157 PubMed CrossRef Richardson, PJ, Kase, H, Jenner, PG 1997 Adenosine A2a receptor antagonists as new agents for the treatment of Parkinson’s disease Trends Pharmacol Sci 18 338 344 PubMed Samadi, P, Gregoire, L, Bedard, PJ 2003 Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems Neuropharmacology 45 954 963 PubMed CrossRef Sandyk, R, Snider, SR 1986 Naloxone treatment of L-dopa-induced dyskinesias in Parkinson’s disease Am J Psychiatry 143 118 PubMed Sañudo-Pena, MC, Tsou, K, Walker, JM 1999 Motor actions of cannabinoids in the basal ganglia output nuclei Life Sci 65 703 713 PubMed CrossRef Savola, JM, Hill, M, Engstrom, M, et al. 2003 Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease Mov Disord 18 872 883 PubMed CrossRef Schapira, AHV, Bezard, E, Brotchie, J, et al. 2006 Novel pharmacological targets for the treatment of Parkinson’s disease Nature Reviews Dug Discovery 5 845 854 CrossRef Schwarzschild, MA, Agnati, L, Fuxe, K, Chen, JF, Morelli, M 2006 Targeting adenosine A2a receptors in Parkinson’s disease Trends Neurosciz 29 647 654 CrossRef Sherzai, A, Bara-Jimenez, W, Sherzai, A, Dimitrova, T, et al. 2003 Adenosine A2A antagonist treatment of Parkinson’s disease Neurology 61 293 296 PubMed Sieradzan, KA, Fox, SH, Hill, MP, et al. 2001 Cannabinoids reduce levodopa-induced dyskinesias in Parkinson’s disease: a pilot study Neurology 57 2108 2111 PubMed
Silverdale MA, Millan MJ, Crossman AR, Brotchie JM (2002) Dopamine D3 receptor blockade, and not stimulation, is associated with anti-parkinsonian activity in the MPTP-lesioned, non-human primate model of Parkinson’s disease. Soc Neurosci Abstr: S63.001
Tan, LC, Protell, PH, Langston, JW, Togasaki, DM 2002 The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys Mov Disord 17 902 909 PubMed CrossRef Thomas, A, Iacono, D, Luciano, AL, Armellino, K, Di Iorio, A, Onofrj, M 2004 Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease J Neurol Neurosurg Psychiatry 75 141 143 PubMed Trugman, JM 2006 Efficacy of istradefylline in levodopa-treated Parkinson’s disease patients with motor response complications: primary efficacy results of the KW-6002-US-013 study Mov Disord 21 S513 Turjanski, N, Lees, AJ 1992 Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias J Neurol Neurosurg Psychiatry 55 413 PubMed CrossRef Ueda, Y, Doi, T, Tokumaru, J, Willmore, LJ 2003 Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures Brain Res Mol Brain Res 116 1 6 PubMed CrossRef Van Blercom, N, Lasa, A, Verger, K, et al. 2004 Effects of gabapentin on the motor response to levodopa: a double-blind, placebo-controlled, crossover study in patients with complicated Parkinson’s disease Clin Neuropharmacol 27 124 128 PubMed CrossRef Vergahen Metman, L, Blanchet, PJ, van den Munckhof, P, et al. 1998a A trial of dextromethorphan in parkinsonian patients with motor response complications Mov Disord 13 414 417 CrossRef Vergahen Metman, L, Del Dotto, P, van den Munckhof, P, et al. 1998b Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease Neurology 50 1323 1326 Verhagen Metman, L, Del Dotto, P, LePoole, K, et al. 1999 Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study Arch Neurol 56 1383 1386 CrossRef Visanji, NP, Gómez-Ramírez, J, Johnston, TH, Pires, D, Voon, V, Brotchie, JM, Fox, SH 2006 Pharmacological characterization of psychosis-like behaviour in the MPTP-lesioned nonhuman primate model of Parkinson’s disease Mov Disord 21 1879 1891 PubMed CrossRef Williams, M, Wright, S, Lloyd, GK 1997 Improved therapies for Parkinson’s disease: life beyond dopamine D2/D3 receptor agonists Trends Pharmacol Sci 18 307 310 PubMed CrossRef Yoshida, S, Okada, M, Zhu, G, Kaneko, S 2005 Effects of zonisamide on neurotransmitter exocytosis associated with ryanodine receptors Epilepsy Res 67 153 162 PubMed CrossRef Zesiewicz, TA, Sullivan, KL, Maldonado, JL, Tatum, WO, Hauser, RA 2005 Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson’s disease Mov Disord 20 1205 1209 PubMed CrossRef Ziegler, M, Fournier, V, Bathien, N, et al. 1987 Therapeutic response to progabide in neuroleptic- and L-dopa-induced dyskinesias Clin Neuropharmacol 10 238 246 PubMed CrossRef